"These results support the remarkable potential for people living with type 2 diabetes." In a 40-week Phase 3 randomized, double-blind, placebo-controlled trial for retatrutide, which included 537 participants, the drug showed average A1C reductions of up to 2% and participants lost an average of 36.6 pounds, or roughly 17% weight loss
Novo Nordisk has been particularly hard-hit, with US sales of Wegovy shrank 2% in the final three months of 2025
That was Aubrey Gordon right here on LiveWire
Frequently Asked Questions What is retatrutide and how does it affect skin tightening
however, the launch addresses a critical need as roughly 2.3 million South African adults live with diabetes, highlighting the significance of improving treatment accessibility
doi: 10.1038/nature11588 84 LupferCThomasPGAnandPKVogelPMilastaSMartinezJet al